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Mast cells (MC) are major participants in the allergic reaction. In addition they possess
immunomodulatory roles in the innate and adaptive immune reactions. Their functions
are modulated through a number of activating and inhibitory receptors expressed on their
surface.This review deals with some of the most recently described receptors, their expres-
sion patterns, ligand(s), signal transduction mechanisms, possible cross-talk with other
receptors and, last but not least, regulatory functions that the MC can perform based on
their receptor expression in health or in disease. Where the receptor role on MC is still not
clear, evidences from other hematopoietic cells expressing them is provided as a possible
insight for their function on MC. Suggested strategies to modulate these receptors’ activity
for the purpose of therapeutic intervention are also discussed.
Keywords: mast cells, activating receptors, inhibitory receptors, ligands, signal transduction, function, co-
stimulation/cross-talk
BACKGROUND
Mast cells (MC) have the uniqueness of being tissue resident cells
packaged with cytoplasmic granules full of preformed mediators
of diverse nature, rich in surface receptors that upon ligand bind-
ing can induce not only the fast release of the stored mediators,
but also the de novo synthesis of arachidonic acid metabolites
and a number of chemokines and cytokines. Therefore they play
a prominent role in maintaining homeostasis, acting as armed
sentinel cells in the tissues, where they reside spanning from
mucosal to connective tissues and more. MC have been histor-
ically associated with allergy, in which the key receptor is FcεRI.
However, their strategic location and potential have clearly demon-
strated that MC are more than the primum movens of allergic
inflammation; they are very important players also in innate and
adaptive immune responses, inflammation, and tissue changes.
MC immunomodulatory roles may result in either negative or
positive outcome for the host, enhancing, or suppressing cer-
tain features of immune/inflammatory responses. A large variety
of receptors especially activating and some inhibiting MC func-
tions, have been described. FcεRI, for IgE activation, and c-kit,
the receptor of the stem cell factor (SCF), serve as fingerprints
in MC characterization and are the topic of other reviews of this
series.
Our purpose is to review herewith the expression pattern, func-
tion, ligand(s), and signal transduction pathways of some of the
most recently described activating and inhibiting receptors iden-
tified to be expressed by the MC from different origins. We have
mainly reviewed the novel activating receptors and discussed just
a few examples of the inhibitory ones. The activating receptors
are comprised of chemokines, interleukins (IL), amines, Toll-Like
Receptors (TLRs), and others (Table 1). For some of the recep-
tors, if known, the physiological and pathological consequences
of their activation and the strategies to modulate their activity
for the purpose of therapeutic intervention are also discussed.
Evidences from other hematopoietic cells expressing these recep-
tors is provided as a possible insight for their function on MC.
Potential cross-talk between activating on one side and activat-
ing and inhibitory receptors (IRs) on the other side is also briefly
considered.
CHEMOKINES RECEPTORS
Chemokines are small cytokine-like proteins that regulate leuko-
cyte trafficking under homeostatic and inflammatory conditions
(Luther et al., 2002; Homey and Bunemann, 2004; for chemokines
receptors (CRs), CRs in MC, see review Juremalm and Nilsson,
2005). CRs, expressed on hematopoietic and lymphatic cells, are
regulated by a variety of inflammatory stimuli (Olson and Ley,
2002). For example CXCR1 and CXCR2 are expressed on most
leukocytes, but appear to be functionally significant only for neu-
trophils, monocytes/macrophages, and MC. CXCR3, CXCR5, and
CXCR6 were found to be expressed on cells of lymphoid lineage
(Olson and Ley, 2002). CXCR3 was later found to be expressed also
by MC (Juremalm and Nilsson, 2005). A defined set of chemokines
(CCL1–5, CCL11, CCL13, CCL17–18, CCL20, CCL22, CCL26–
27, CX3CL1) was identified to initiate and perpetuate atopic skin
inflammation (Homey et al., 2006, 2007).
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Table 1 | Structural functional data, expression, ligand, and function of some MC receptors discussed in the review.
Receptor Ligand Structural functional data MC expression Function
Chemokines
receptors
For
CXCR3-CXCL9,
CXCL10, and
CXCL11 (Meiser
et al., 2008)
GPCR E.g., CXCR3 protein: human lung MC
(Juremalm and Nilsson, 2005)
Migration (Juremalm et al.,
2002), signaling events (Lacotte
et al., 2009) partial degranulation
(Willox et al., 2010)
IL-15R IL-15 α Chain, β chain, γ chain Protein: mBMMC Expression assumed by
function: hCBMC (Jackson et al., 2005)
Migration (Jackson et al., 2005),
enhancement of Th1 response,
inhibition of allergic inflammation
in a murine model of asthma
(Ishimitsu et al., 2001)
IL-18R IL-18 Dimeric complex of IL-18Rα,
IL-18Rβ
mRNA and protein: mouse mucosal MC and
immature MC (Wiener et al., 2008)
Production of IFN γ, GM-CSF,
TNF-α and IL-1, IL-13, and/or IL-4
(Nakanishi et al., 2001; Akdis
et al., 2011)
IL-33R (ST2) IL-33 Complex: ST2 and IL-1RAcP Protein: mBMMC (Liew et al., 2010) Degranulation and
proinflammatory cytokine
production and release (Hsu
et al., 2010; Liew et al., 2010)
TSLPR TSLP Complex: TSLPR with IL-7Rα mRNA: mBMMC (Knisz et al., 2009). Protein:
human peripheral blood and hCBMC
(Allakhverdi et al., 2007)
Increasing of pro-inflammatory
cytokines (Allakhverdi et al.,
2007) production and Th2
response (Ziegler and Artis, 2010)
TLR Bacterial and viral
proteins
Extracellular leucine rich
region, cytoplasmic domain
that consists of three
homologous regions (box 1,
2, 3)
TLR2 and TLR4 mRNA:immature and mature
MC from murine and human origins
(Supajatura et al., 2002). TLR2 protein:
hCBMC and nasal polyps MC (McCurdy
et al., 2003). TLR2 and TLR4 protein:murine
intestine MC and murine and rat peritoneal
MC (Pietrzak et al., 2011)
de novo synthesis and release of
cytokines (McCurdy et al., 2001;
Supajatura et al., 2002)
CD48 2B4, FimH, S.
aureus, and M.
tuberculosis
toxins
Glycosyl-phosphatidyl-inositol
(GPI)-anchored protein
Protein: BMMC and human peripheral blood
MC
Allergic effector unit formation,
stimulation of mediator release
(Elishmereni et al., 2011)
S1P2R S1P GPCR Protein: mBMMC and RBL-2H3 (Jolly et al.,
2004), hMC (Oskeritzian et al., 2010), and
hematopoietic progenitors (Price et al., 2009)
Degranulation (Wang et al., 2012)
and chemokine and cytokine
release (Oskeritzian et al., 2010)
trafficking and migration (Spiegel
and Milstien, 2011)
HR (H1, H2, H3,
H4)
Histamine GPCR H1R mRNA and protein: (Lippert et al., 2004)
low in human skin MC (Lippert et al., 2004;
Gibbs and Levi-Schaffer, 2012), higher in
HMC-1 cells
H1, H2-intracellular calcium
mobilization (Tilly et al., 1990)
H2R mRNA and protein: human skin MC,
and HMC-1 cells (Lippert et al., 2004)
H3-autoregulation of histamine
release (Ohkubo et al., 1994)
H3R protein: in brain mast cells (Rozniecki
et al., 1999)
H4-chemotaxis and intracellular
calcium mobilization in mMC
(Nordlind et al., 2008),
recruitment of effector cells in
human (Hofstra et al., 2003)
H4R mRNA: mouse MC, hCBMC, and
HMC-1 (Hofstra et al., 2003; Gibbs and
Levi-Schaffer, 2012), human skin MC (Lippert
et al., 2004)
(Continued)
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Table 1 | Continued
Receptor Ligand Structural functional data MC expression Function
5HTR Serotonin GPCR mRNA: mBMMC and human CD34+-derived
MC (Kushnir-Sukhov et al., 2006)
Cell migration (Nordlind et al.,
2008)
Purinergic P1 Adenosine P1: GPCR Adenosine receptors-A1protein: canine BR
mastocytoma
hCBMC implicating the A1R in
potentiation, and A2BR receptor
in the inhibition of
anti-IgE-induced degranulation
(Yip et al., 2009; Hua et al., 2011)
A2a protein: HMC-1, RBL-2H3, mBMMC
A2b protein: canine BR mastocytoma,
HMC-1, RBL-2H3, mBMMC
A3 protein: mastocytoma, RBL-2H3,
mBMMC (Forsythe and Ennis, 1999; Hua
et al., 2011)
P2X ATP P2X: ion pore E.g., P2X1, P2X4, P2X7 protein:
hCBMC(Bulanova and Bulfone-Paus, 2010).
P2X1–4, P2X6–7 mRNA: mBMMC (derived
from C57BL/6 mice)
Degranulation, apoptosis
(Bulanova et al., 2009)
P2Y ATP, ADP, UTP,
UDP,
UDP-glucose
P2Y: GPCR P2Y receptors (with the exception of P2Y2)
protein: mBMMC
Degranulation, P2Y13 in RBL-2H3
Ca2+ release and release of
β-hexosaminidase
P2Y1, P2Y2 P2Y12, P2Y13, and P2Y11:
hCBMC (Feng et al., 2004)
P2Y2: mediation of chemotaxis
in mBMMC and CD34+
progenitors. (Bulanova and
Bulfone-Paus, 2010)
CD203c NAD and
nucleotide sugars
Type II-phosphatidyl-inositol
transmembrane proteins with
catalytic domain and a
C-terminal endonuclease-like
domain
mRNA and protein: overexpressed on
neoplastic MC in patients with systemic
mastocytosis (Hauswirth et al., 2008)
Cleavage of phosphodiester and
phosphosulfate bonds (Buhring
et al., 2004)
CRHR CRH GPCR mRNA and protein: hCBMC and LAD-2
(Asadi et al., 2012)
Production and release of IL-8,
TNF, VEGF. Induction of NK-1
gene expression (Asadi et al.,
2012)
Endocannabinoids
receptors
Endocannabinoids GPCR Protein: on human skin MC (Sugawara et al.,
2012)
Inhibition of MC maturation and
activation, regulation of SCF
expression (Sugawara et al.,
2012)
mRNA, messenger ribonuclear acid; MC, mast cell; IL, interleukin; GPCR, G protein coupled receptor; H, human; M, mouse; BMMC, bone marrowmast cells; CBMC,
cord blood mast cells; IFN γ, interferon-gamma; GM-CSF, granulocyte-macrophage colony-stimulating factor; TNF α, tumor necrosis factor α; TSLPR, thymic stromal
lymphopoietin receptor; TLR,Toll-like receptor; 5HTR, 5-hydroxytryptamine receptors; ATP, ADP, adenosine 5′-triphosphate, adenosine diphosphate; UTP, UDP, uridine
triphosphate, uridine diphosphate; NAD, nicotinamide adenine dinucleotide; CRHR, corticotropin-releasing hormone receptor; CRH, corticotropin-releasing hormone;
SCF, stem cell factor; S1P, sphingosine-1-phosphate; HR, histamine receptor.
Human MC (hMC) from different origins express at least nine
CRs, i.e., CXCR1–4, CX3CR1, CCR1 (further detailed in MC
Co-Stimulation), CCR3–5 that may be activated by the respec-
tive chemokines, i.e., CXCL1, CXCL5, CXCL8, CXCL14, CX3CL1,
CCL5, and CCL11 (Juremalm and Nilsson, 2005). Interestingly,
activation of CRs on MC can not only induce their chemotaxis,
but also other stimulatory responses. For example, the activation
of CXCR3 and CCR2, besides migration also induces human cord
blood MC (hCBMC) signaling events or even partial degranula-
tion in the absence of antigen (Willox et al., 2010). The expression
of CXCR3 and RANTES (also known as CCL5) on MC is impor-
tant especially in the migration of MC precursors in the tissues
where they undergo final maturation (Juremalm et al., 2002).
CCL5/RANTES can induce MC migration through interactions
with CCR1 and CCR4 (Juremalm et al., 2002).
CXCR3 is a seven transmembrane (TM) domain G protein cou-
pled receptor (GPCR) that binds the pro-inflammatory, non-ELR
motif of CXC chemokines: CXCL9, CXCL10, and CXCL11 (Meiser
et al., 2008) and was found to be sensitive to pertussis toxin (Ptx;
Willox et al., 2010). Recently, two different variants of CXCR3 have
been identified in human: CXCR3B and CXCR3-ALT, both origi-
nating from the same gene and produced by alternative splicing of
the CXCR3 mRNA (Willox et al., 2010). CXCR3 activation leads
to Gαi protein internalization with subsequent calcium influx
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and triggering of mitogen-activated protein kinases (MAPK) and
AKT (Protein kinase B, PKB) cascade resulting in cytoskeleton
rearrangement and cell movement (Lacotte et al., 2009). Upon
activation of this CR, cross-talk between the CXCR3 and FCεRI is
possible due to the fact that both these receptors involve phospho-
inositide 3-kinases (PI3Ks) signaling. CXCR3 is highly expressed
in human lung MC that reside in proximity to the smooth muscle
in asthmatics, but is not expressed in human bone marrow MC
(hBMMC; Brightling et al., 2005). In human lungs, CXCR3 on
MC mediates their migration toward chemokines-secreting airway
smooth muscle regions. Additionally, CXCL10 has been shown to
be expressed in that region in bronchial asthma biopsy specimens
and ex vivo in smooth muscle cells from asthmatics compared
to the ones derived from healthy volunteers (Okayama et al.,
2008). Because of the importance of chemokines in recruiting
inflammatory cells and MC precursors into the tissues, neutraliza-
tion of chemokines, or antagonists of their receptors is an active
investigational field in the pharmaceutical industry.
INTERLEUKIN RECEPTORS AND TSLPR
Interleukins are secreted glycoproteins that bind to their specific
receptors and play a role in the communication among leukocytes.
In the past decade, a number of new cytokines have been described
such as IL-15, IL-18, IL-7, IL-33. Importantly, MC display the
receptors for some of the newly identified IL.
THE IL-15 RECEPTOR
The classic IL-15 receptor (IL-15R) consists of a unique α chain,
a β chain, and a common γ chain which is shared with the IL-2
receptor (Lorenzen et al., 2006). IL-15R signaling requires DAP10-
associated proteins since the IL-15 signaling pathway phosphory-
lates DAP10 through JAK3. Once activated, IL-15R triggers the
activation of JAK3-STAT5 signaling pathway that relays informa-
tion to the nucleus (Colucci, 2007). IL-15R is expressed in B, T
cells, and natural killers cells (NK) and its activation results in
cell proliferation and differentiation. IL-15R was recently reported
to be expressed on mouse BMMC (mBMMC). It has not yet
been reported whether hCBMC express the same receptors. How-
ever, IL-15 induced migration of both mBMMC and hCBMC in
a dose-responsive and biphasic manner, supports the possibility
that this effect is mediated by two distinct IL-15R with different
affinities to IL-15 (Jackson et al., 2005). Interestingly, in stimu-
lated dendritic cells (DC), IL-15, and IL-15Rα are preassembled in
complexes within the endoplasmic reticulum/Golgi before being
released from the cells. In NK, membrane bound IL-15-IL-15Rα
complexes, and not the soluble ones, trigger activation (Mortier
et al., 2008).
The ligand of IL-15R, IL-15, is produced in human by both
non-immune cells (keratinocytes and skeletal muscle cells) and
by immune cells (monocytes, and activated CD4+ T cells) in
response to signals that induce innate immunity (Akdis et al.,
2011). IL-15 is also produced by murine MC, especially after stim-
ulation with lipopolysaccharide (LPS; Orinska et al., 2007). IL-15
in MC induces an intracrine signal that downregulates chymase-
dependent, MC-mediated innate immunity (Orinska et al., 2007).
In Il-15−/− mice, the absence of IL-15 in MC increases chymase
activities, leading to greater MC bactericidal responses, increased
processing, and activation of neutrophil-recruiting chemokines,
and improved sepsis survival (Orinska et al., 2007).
IL-15 is associated with autoimmune and inflammatory dis-
eases and was recently shown to be upregulated in T cell-mediated
inflammatory disorders, such as rheumatoid arthritis (RA) and
inflammatory bowel diseases (Waldmann, 2004). In rheumatoid
synovial tissue explants, αIgE induced MC activation induces
changes in the amounts of released tryptase, TNFα, and IL-1β
by a proportion of mononuclear inflammatory cells, but not in
the amount of IL-15 (Woolley and Tetlow, 2000). IL-15 is also
associated with the development of X-linked severe combined
immunodeficiency (Akdis et al., 2011). Overexpression of IL-15
in vivo enhances Th1 responses, which inhibit allergic inflamma-
tion in a murine model of asthma (Ishimitsu et al., 2001). In a
human psoriasis xenograft model, the anti IL-15 antibody 146B7
was found to be involved in the reduction of the severity of the dis-
ease (Villadsen et al., 2003). Additionally, HuMax-IL-15, a human
IgG1 anti-IL-15 monoclonal antibody, that in vitro was able to neu-
tralize exogenous and endogenous IL-15, has been used for clinical
trials in patients with RA to perform a phase I–II dose-escalation
trial (Baslund et al., 2005; Waldmann, 2006).
THE IL-18 RECEPTOR
IL-18 receptor (IL-18R) expressed on MC belongs to the IL-
1 receptor (IL-1R) family (Thomassen et al., 1998). IL-18Rα is
the binding chain and together with IL-18Rβ form a high affin-
ity heterotrimeric complex with the ligand IL-18. This complex
recruits the intracellular adapter molecules myeloid differentiation
primary response protein 88 (MyD88), IL-1 receptor-associated
kinases (IRAK) and tumor necrosis factor receptor associated fac-
tor 6 (TRAF6) which results in the activation of p38 MAPK, JUN
N-terminal kinase (JNK), and/or nuclear factor kB (NF-kB; Arend
et al., 2008). IL-18R is expressed on T cells, NK cells, macrophages,
epithelial cells, chondrocytes (Kunikata et al., 1998), and MC
(Helmby and Grencis, 2002).
The ligand of IL-18R, IL-18, is an IFN-γ-inducing factor and a
potent cytokine that is produced by monocytes/macrophages as a
reaction to different microbial components and therefore plays a
major role in the innate immune responses to pathogens (Arend
et al., 2008). Also Kupffer cells, keratinocytes, osteoblasts, astro-
cytes, and DC express IL-18 (Akdis et al., 2011). The regulation
of IL-18 biological activity is carried out by caspase-1-mediated
cleavage of pro-IL-18 to the mature protein. Human chymase can
also cleave pro-IL-18 to the active protein (Omoto et al., 2006). IL-
18 binding protein (BP) is a soluble protein that by binding mature
IL-18 prevents its binding to receptor, and therefore serves as a nat-
ural inhibitor (Novick et al., 1999). IL-18BP displays four isoforms
in humans and two in mice that are the result of alternative splicing
of mRNA and which mainly differ in the C-terminal region. IL-18
indirectly increases the production of its own inhibitor in a feed-
back loop via INFγ secretion. IL-18R activation is able to induce
in addition to IFNγ, also GM-CSF, TNFα, and IL-1 production. In
addition it can induce IL-13 and/or IL-4 production by NK, MC,
and basophils. It can therefore enhance innate immunity and both
Th1 and Th2 driven immune responses (Nakanishi et al., 2001).
IL-18 has been associated with autoimmune diseases or inflam-
matory disorders, bronchial asthma (Harada et al., 2009), atopic
Frontiers in Immunology | Molecular Innate Immunity August 2012 | Volume 3 | Article 238 | 4
Migalovich-Sheikhet et al. Receptors on mast cells
dermatitis (Konishi et al., 2002), RA (Gracie et al., 1999; Plater-
Zyberk et al., 2001), psoriasis (Ohta et al., 2001), multiple sclerosis
(Karni et al., 2002), and type I diabetes (Altinova et al., 2008; Akdis
et al., 2011). Regarding allergy, interestingly IL-18 contributes to
the spontaneous development of IgE/signal transducer and acti-
vator of transcription (STAT6)-independent atopic dermatitis-like
inflammatory skin lesion (Konishi et al., 2002).
In conclusion, IL-18/IL-18R regulation, if carried out by selec-
tive antagonists, can possibly be considered as a good pharmaco-
logical target in either Th1 or Th2 driven conditions.
IL-33 RECEPTOR
IL-33 receptor (IL-33R) termed also ST2 is a member of the IL-
1R family, and TLR/IL-1R (TIR) superfamily (Liew et al., 2010). It
binds IL-33 as a heterodimer consisting of ST2 and IL-1R accessory
protein. The signaling cascade of ST2 activation involves recruit-
ment of MyD88, TRAF6, and IRAK. This leads to NF-kB activation
and the activation of MAPK p38, signal-regulated kinase ERK, and
JNK. ST2 is expressed on basophils, MC, eosinophils, NK cells, Th2
cells, DC, and nuocytes (Kunikata et al., 1998; Akdis et al., 2011).
Mouse BMMC express high levels of ST2 and respond directly
to IL-33 to produce a spectrum of inflammatory cytokines and
chemokines (IL-1, IL-6, IL-13, TNF, CCL2, and CCL3; Liew et al.,
2010). In vivo, IL-33 treatment exacerbated collagen-induced
arthritis in ST2−/− KO mice engrafted with MC from WT but
not from ST2−/− mice, a fact that was associated with eleva-
tion in expression levels of pro-inflammatory cytokines (Xu et al.,
2008). The ST2 ligand, IL-33, is a pro-inflammatory cytokine that
activates Th2 response-inducing cells. IL-33 activation induces
mBMMC and the murine MC line MC/9 proliferation and Th2
cytokine production including IL-4, IL-5, IL-6, but not IL-33 itself
(Hsu et al., 2010). On the other hand mBMMC produce IL-33
in response to IgE activation, which requires calcium influx or
ionomycin activation (Hsu et al., 2010).
IL-33/ST2 pathway is critical for the development of IgE-driven
tissue inflammation during passive cutaneous anaphylaxis that is
a strictly MC-dependent model (Hsu et al., 2010). Levels of sol-
uble ST2 increase in inflammatory conditions such as systemic
lupus erythematosus (SLE), RA (Xu et al., 2008), idiopathic pul-
monary fibrosis (Tajima et al., 2003), asthma (Oshikawa et al.,
2001), progressive systemic sclerosis, Behcet’s disease, Wegener’s
granulomatosis, severe trauma, and sepsis (Akdis et al., 2011).
Importantly, in all of these conditions MC activation and role
have been illustrated. IL-33 release is elevated in skin of patients
with atopic dermatitis (Liew et al., 2010). Constant mechani-
cal microtrauma and destruction of skin barrier induce IL-33
release and a pro-inflammatory response. In addition, IL-33 may
play a role in psoriasis-like plaque inflammation (Hueber et al.,
2011).
IL-33 has been classified as an alarmin/danger signal (Cevikbas
and Steinhoff, 2012) since it is released by cells undergoing necro-
sis and it is inactivated by caspases during cell apoptosis (Liew
et al., 2010; Hueber et al., 2011). However, it is evident that IL-33
is released not only from necrotic cells, but also from living cells
and therefore acts as a classical cytokine (Liew et al., 2010). Its
importance in allergy is the current topic of high interest partly
due to its effects on the MC.
TSLP RECEPTOR
TSLP receptor (TSLPR) is the receptor of TSLP that is an IL-7-like
cytokine initially identified in the culture supernatant of a thymic
stromal cell line (He and Geha, 2010). TSLPR has a low affinity to
TSLP, but together with IL-7Rα they generate high affinity bind-
ing sites and trigger signaling (Park et al., 2000). Cross species
homology of TSLP and its receptor is relatively low (about 40%;
He and Geha, 2010; Ziegler and Artis, 2010), but the fact that both
in human and in mouse IL-7Rα is required suggests that human
TSLP and TSLPR are orthologs to mouse TSLP and TSLPR. The
signaling cascade of these receptors is not completely clear and
no Janus kinases (JAK) are activated (Isaksen et al., 2002). It has
however been shown that receptor engagement can activate the
transcription factor STAT3 in human and STAT5 in mouse and
human (Isaksen et al., 2002). In addition, it can also induce the
expression of common genes (such as Cish; Isaksen et al., 2002).
TSLP receptor is expressed on hematopoietic cell lineages,
including B cells, T cells, MC, eosinophils, and DC (Taylor et al.,
2009). mBMMC were shown to express TSLPR mRNA (Knisz et al.,
2009). TSLPR and IL-7Rα chain expression were determined at the
mRNA level on human peripheral blood and hCBMC (Allakhverdi
et al., 2007). In spite of these reports, human peripheral blood
derived MC (hpbMC) and the HMC-1 cell line (hMC leukemia-1)
were found by us to express TSLPR, but not IL-7R (Levi-Schaffer,
F., Soumelis, V., Levy, I., unpublished data). At the protein level,
TSLPR was also reported to be expressed in vivo on MC infil-
trating the bronchial mucosa of asthmatic patients, as revealed
by immunostaining of biopsy specimen (Allakhverdi et al., 2007;
Comeau and Ziegler, 2010; Shikotra et al., 2012).
It has been found that MC infiltrating to the mucosal gland
stroma and airway smooth muscle in asthma not only express high
levels of TSLP mRNA, but can also respond to TSLP (Rochman
and Leonard, 2008). TSLP can directly activate hMC to produce
pro-inflammatory Th2 cytokines and chemokines in the presence
of IL-1β and tumor necrosis factor α (TNF-α), in a way that mim-
ics inflammation conditions (Allakhverdi et al., 2007). Various cell
types can produce TSLP: endothelial, epithelial cells and epider-
mal keratinocytes, airway smooth muscle cells, fibroblasts, DC,
trophoblasts, and cancer or cancer-associated cells (Takai, 2012).
hMC express TSLP mRNA, which is upregulated upon cross-
linking of the IgE receptor. Pre-incubation with IL-4 results in
significant upregulation of IgE-mediated TSLP protein and mRNA
expression (Okayama et al., 2009; Comeau and Ziegler, 2010).
TSLP plays a significant role in initiation of allergic inflamma-
tion and is very important to cells such as the MC, due to its high
expression in the interfaces between the body and environment
and its ability to lead to Th2 responses (Ziegler and Artis, 2010).
Different studies have shown that asthma, allergic rhinitis, and
atopic dermatitis are characterized by an increased expression of
TSLP in the inflamed tissue (Ziegler and Artis,2010; Le et al.,2011).
Mice overexpressing TSLP on TCRβ−/− background, develop der-
mal inflammation and skin infiltrates of MC and eosinophils (Yoo
et al., 2005). MC deficient mice failed to upregulate TSLP in nasal
epithelium after allergen challenge in a model of allergic rhinitis
(Ziegler and Artis, 2010). In asthma it was demonstrated that MC
play an important role in TSLP production (Shikotra et al., 2012).
TSLP levels are increased in human asthma and correlate with the
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increase in expression of Th2 cytokines and disease severity (Ying
et al., 2005, 2008; Corrigan et al., 2009; Fang et al., 2010).
Blocking of TSLP signaling using TSLPR-immunoglobulin in
murine asthma model, was shown to regulate pulmonary DC
function and to reduce eosinophilic airway inflammation and
Th2 differentiation significantly (Zhang et al., 2011). Additionally,
TSLP/TSLPR interaction influences the function of cells in host
protection against helminth parasites, and modulates gut home-
ostasis in conditions in which MC are involved (Comeau and
Ziegler, 2010). Therefore it appears that MC displaying TSLPR
and producing TSLP have a potent weapon in addition to FcεRI
in orchestrating the allergic reactions. As a consequence the TSLP
axis is a very promising candidate for anti-allergic intervention.
Notably, TSLP and IgE stimulated MC can induce OX40 lig-
and (OX40L) expression on DC. (Ito et al., 2005; Edwards, 2008).
OX40 receptor and its ligand OX40L belong to the superfami-
lies TNF receptor and TNF respectively (Godfrey et al., 1994)
and were shown to have a crucial role in allergic inflammation.
OX40/OX40L interaction can trigger the differentiation of some
inflammatory Th2 cells in the lymph nodes. (Liu, 2007; Wang and
Liu, 2007) OX40L on MC and OX40 on T regulatory cells cross-
talk can induce T cells activation by hMC in vitro (Kashiwakura
et al., 2004) and inhibit FcεRI-dependent MC degranulation both
in vitro and in vivo (Gri et al., 2008). Recently, Ilves and Harvima
(2012) showed that there are more OX40 positive cells in the der-
mis from AD lesions than in healthy looking dermis, which does
not correlate with clinical severity of AD.
TOLL-LIKE RECEPTORS AND OTHER BACTERIAL AND VIRAL
RECEPTORS
As key protagonists of innate immunity, MC play a pivotal role
in anti-infection defense and “danger” responses. MC reactiv-
ity against bacteria have been more characterized than the ones
against viruses, although both of them are classically mediated by
TLRs (Akira and Takeda, 2004), a family of pattern recognition
molecules.
Toll-like receptors and IL-1R have a conserved cytoplasmic
domain that consists of three homologous regions (boxes 1, 2, 3)
and an extracellular domain that differs: TLRs have tandem repeats
of leucine rich regions, while IL-1R has three immunoglobulin like
domains (Akira and Takeda, 2004). Stimulation of TLR triggers the
association of MyD88, IRAK4, and IRAK1 signaling leading to the
NF-kB activation and gene expression (Akira and Takeda, 2004).
MC signaling via TLRs involves also ITAM-containing molecule
DAP12 phosphorylation that activates syk, which is a critical mol-
ecule of MC activation (Smrz et al., 2010). This would suggest a
cross-talk between TLRs and receptors that employ DAP12 as a
transducer molecule.
TLR2 and TLR4 expression has been detected at the mRNA
level in immature and mature MC from murine and human ori-
gins (Supajatura et al., 2002). At the protein level, TLR2 was found
to be expressed in hCBMC and in nasal polyps MC (McCurdy
et al., 2003). TLR2 and TLR4 are found in murine intestine MC
and murine and rat peritoneal MC (Pietrzak et al., 2011). TLR sig-
naling events induce cytokine production (Supajatura et al., 2002).
TLR2 can be activated by prolonged stimulation with bacterial wall
components, such as LPS and peptidoglycan (PGN), resulting in
de novo synthesis and release of various cytokines. It was shown
that PGN was able to induce degranulation of mBMMC via TLR2
accompanied by Ca2+ influx, whereas the activation of MC by LPS
via TLR4 did not lead to degranulation (Supajatura et al., 2002).
Cytokine exposure of MC can also upregulate the expression of
TLRs. For example, IL-6 treatment of mMC induces an increase
in TLR4 expression, whereas exposure to TNF does not influence
the TLR2 and TLR4 protein levels (McCurdy et al., 2001). On the
contrary, exposure of MC to CCL5 resulted in decreased expres-
sion of both TLR2, following 24 h incubation, and TLR4 level,
following 12 and 24 h incubation (McCurdy et al., 2001).
CD48
CD48, a CD2-like molecule, is a 40KD glycosyl-phosphatidyl-
inositol (GPI)-anchored protein, expressed on the surface of
hematopoietic cells (recently reviewed in Elishmereni and Levi-
Schaffer, 2011). The CD48 structure combines a distal V-like
domain with a C2-like domain containing conserved cysteine
residues that form disulfide bonds. It lacks a TM domain and
is attached to the cell surface by a glycolipid, GPI, restricted to the
outer leaflet of the membrane bilayer (Shin and Abraham, 2001).
CD48 is found also in soluble form, due to its cleavage upon acti-
vation. Stimulated CD48 associates to the kinase LCK and leads to
tyrosine phosphorylation (Elishmereni and Levi-Schaffer, 2011).
CD48 is illustrated here since in MC, CD48 was first described
to be involved in innate immunity as it binds FimH of E. coli.
This interaction triggers a strong TNF-α release and the uptake
of this Gram-bacteria (Malaviya et al., 1999; Malaviya and Abra-
ham, 2001; Proft and Baker, 2009). CD48, has also been impli-
cated in MC interactions with M. tuberculosis, which triggers the
release of several pre-stored mediators, such as histamine and β-
hexosaminidase, and the de novo synthesis of cytokines, such as
TNF-α and IL-6 (Munoz et al., 2003). Later on we found that
S. aureus, a Gram+ bacteria, and its toxins bind to CD48 and
TLR2 on hCBMC causing subsequent release of pro-inflammatory
cytokines (Rocha-de-Souza et al., 2008). CD48 is overexpressed in
murine asthma and was defined as a signature gene in this con-
dition (Zimmermann et al., 2003). The CD48 ligand in human is
2B4, expressed by several hematopoietic cells. CD48/2B4 interac-
tions taking place between MC and eosinophils are important in
allergic inflammation giving rise to the physical formation of the
allergic effector unit (AEU) between these two cells (Elishmereni
et al., 2011). CD48-2B4 binding induces degranulation of MC and
increases eosinophil survival and activation (Elishmereni et al.,
2011). In a murine model of allergic asthma, treatment with neu-
tralizing CD48 Ab dramatically inhibited the lung inflammation
(Munitz et al., 2007). Therefore it seems that CD48 is a good can-
didate to be blocked on MC in order to avoid both AEU formation
and bacterial invasion, with this last property being particularly
helpful in allergic conditions, such as atopic dermatitis, that are
commonly associated with S. aureus infection.
S1P RECEPTORS
S1PR1–5 are GPCRs of sphingosine-1-phosphate (S1P). Secretion
of S1P by MC can modulate their function by binding to S1PR1
and S1PR2 found on MC, in an autocrine fashion (Spiegel and
Milstien, 2011). It was shown on DC that there is a cross-talk
Frontiers in Immunology | Molecular Innate Immunity August 2012 | Volume 3 | Article 238 | 6
Migalovich-Sheikhet et al. Receptors on mast cells
between S1PR2 and S1PR1, when upregulation of S1PR2 activates
the small GTPase RHO leading to translocation of Four and a
Half LIM domains protein 2 (FHL2) to the nucleus and down-
regulates S1PR1 expression. On the other hand, downregulation
of S1PR2 increases S1PR1 expression and RAC activation (Spiegel
and Milstien, 2011).
S1P1 is involved in the migration of MC toward low con-
centrations of antigen, while S1P2 participates in FcεRI-induced
degranulation (Jolly et al., 2005; Olivera, 2008). S1P released from
MC after cross-linking of FcεRI, and their S1P2 receptors are criti-
cal for degranulation and chemokine, cytokine, and lipid mediator
release from activated human and rodent MC (Oskeritzian et al.,
2010). Additionally, blocking of the S1P–S1PR2 axis was shown
to drastically reduce circulating levels of histamine in a mouse
anaphylaxis model indicating that MC were inhibited (Oskeritz-
ian et al., 2010). The S1PR2 activation plays a role in anti-viral
immunity: the viral membrane lipid sphingomyelin that is con-
verted in the cell membrane to S1P can then activate the S1PR2
in an autocrine manner to stimulate MC degranulation (Wang
et al., 2012). S1P–S1PR1 axis has been shown to be expressed on
and to control the trafficking and migration of numerous types
of immune cells, including T and B lymphocytes, natural killer T
cells, DC, macrophages, neutrophils, hematopoietic progenitors,
MC, and osteoclasts (Spiegel and Milstien, 2011).
Therefore, S1PR can offer an interesting pharmacological target
for a number of immune diseases. For example the S1PR2 antago-
nist JTE013 significantly inhibited H2O2-induced permeability in
the rat lung perfused model (Sanchez et al., 2007). More studies
are under way to exploit the blockage of the S1P and its receptors
in many diseases and notably in allergy.
AMINES’ RECEPTORS
Among the mediators extensively identified with the function of
MC in allergy, histamine in humans and rodents, and serotonin
especially in rodents are key factors influencing the activity of a
number of target cells/organs. MC not only produce these two
potent amines but also display some of their receptors (Gibbs and
Levi-Schaffer, 2012; Ritter et al., 2012).
HISTAMINE RECEPTORS
Histamine receptors (HRs) are GPCRs with seven TM-spanning
helices. Until now, four subtypes of human HRs have been identi-
fied: H1R, H2R, H3R, and H4R. H1R and H2R have been the focus
of many studies (recently reviewed in Gibbs and Levi-Schaffer,
2012). Fewer studies have been performed on the H3R and even
less on the newest identified one, H4R. Regarding HRs expres-
sion by MC, not much work had been carried out until the recent
discovery of H4R.
H1R expression has been described on human skin MC to be
low (Lippert et al., 2004; Gibbs and Levi-Schaffer, 2012), while on
the HMC-1 cells it is higher (Lippert et al., 2004). H1R antagonists
can inhibit MC activation and therefore can be used as anti-
allergic/MC stabilizing drugs (Levi-Schaffer and Eliashar, 2009),
even though some of them might increase cellular cAMP in com-
petitive antagonism with H2R. In cholangiocytes, H1R acts by
Gαq activating IP(3)/Ca2+, whereas H2R activates Gα(s) stimu-
lating cAMP (Francis et al., 2012). Additionally, it was reported
that H2R can activate both adenylate cyclase and phospholipase
C signaling pathways via separate GTP-dependent mechanisms
(Wang et al., 1996). Interestingly, via the H2R, histamine displays a
net inhibitory action on MC (Gibbs and Levi-Schaffer, 2012). H2R
is expressed on human skin MC, on HMC-1 cells and basophils,
and perhaps on human lung MC. The H2 agonist impromidine
was shown to inhibit MC activated with compound 48/80 and this
inhibition was reversed by the histamine antagonists (Masini et al.,
1982).
H3R and H4R have about 40% sequence homology and are
functionally related (Morse et al., 2001; Zhu et al., 2001). Both
of them are activated by α-methylhistamine (H3/4R agonist) and
inhibited by thioperamide (antagonist). Mouse MC were reported
to express H4R and to lack H3R expression (except brain MC that
do express H3R; Pillot et al., 2002; Gibbs and Levi-Schaffer, 2012).
In mouse MC, the H4R has been shown to couple to Ca2+ mobi-
lization, but not to cAMP, in a Ptx-sensitive manner (Hofstra et al.,
2003; Rosethorne and Charlton, 2011). H4R in mouse MC affects
chemotaxis and intracellular calcium mobilization, and although
it is not involved in their degranulation, the receptor activation and
subsequent histamine release leads to recruitment of effector cells,
especially eosinophils, rich in H4R to the site of chronic allergic
inflammation (Hofstra et al., 2003). H4R activation of murine MC
increases leukotriene B4 (LTB4) release and supports neutrophil
recruitment induced by zymosan (Takeshita et al., 2003). H4R
blockade was shown to decrease MC and eosinophil migration to
the airway epithelial tissue after guinea pigs allergen exposure (Yu
et al., 2008). Blocking the H4R also decreases the MC migration in
presence of CXCL12 in vitro (Godot et al., 2007). Therefore, H4R
plays a role in allergy by mediating the recruitment of cells to the
site of allergic inflammation and also by controlling this last effect
together with H1R. It has recently been demonstrated that in a
mouse model of allergic pruritus, the H4R antagonist JNJ7777120
is more effective in reducing the response to histamine release than
H1R antagonist (Dunford et al., 2007). It is foreseen that combi-
natorial therapy with both H4R antagonists – when available for
human use – to target mostly MC and eosinophils and H1R antag-
onists could be a potent new therapy for some allergic responses
rather than just H1R antagonists.
SEROTONIN RECEPTORS (5HTRs)
Serotonin is a neurotransmitter that can modulate a number of
functions also outside the neural system (Berger et al., 2009). Sero-
tonin receptors, also known as 5-hydroxytryptamine receptors
(5HTRs), are classified in humans into seven main families with
an additional subtype for two of the families (IUPHAR Receptor
Database, 2008). Although 5HTRs have been known for a long
time they have only recently been characterized on MC. With the
exception of the 5HTR3, a ligand gated ion channel, all other sero-
tonin receptors are GPCRs (Ritter et al., 2012) that activate an
intracellular second messenger cascade to produce an excitatory
or inhibitory response.
5HT1AR is negatively coupled to adenyl cyclase via Gi and it is
expressed on hMC (Kushnir-Sukhov et al., 2006; Ritter et al., 2012)
and mBMMC (Kushnir-Sukhov et al., 2006). It is expressed on MC
in normal skin and its activation induces inflammation, due to MC
migration and adherence in the site of inflammation, but it does
not involve degranulation (Nordlind et al., 2008). Even though
a still controversial issue, hMC were found to be able to secrete
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serotonin both in IgE-dependent and independent manner (Aske-
nase et al., 1991; Matsuda et al., 1995). This was further shown to
activate effector T cells and macrophages (Young and Matthews,
1995), and also could show the possibility of an autocrine regu-
lation of the MC. 5HT/5HT1AR are involved in allergic contact
eczema, atopic eczema, psoriasis (Nordlind et al., 2008), and also
expressed in human mastocytosis (Ritter et al., 2012).
PURINERGIC RECEPTORS AND ATP-HYDROLYZING ENZYMES
PURINERGIC RECEPTORS
Purinergic receptors, also known as purinoceptors, are a family of
plasma membrane molecules involved in several cellular functions
such as vascular reactivity, apoptosis, and cytokines secretion. The
term, purinergic receptor was originally introduced to illustrate
specific classes of membrane receptors that mediate relaxation of
gut smooth muscle as a response to the release of Adenosine 5′-
triphosphate (ATP) – P2R receptors or adenosine – P1R (King
and Burnstock, 2002). There are three known distinct classes of
purinergic receptors, referred to as P1, P2X, and P2Y receptors
comprehending different subtypes (Bulanova and Bulfone-Paus,
2010). P2Y receptors, in addition to ATP, respond also to differ-
ent nucleotides (ADP, UDP, UTP, UDP, and UDP-glucose). P1 and
P2Y are GPCRs whereas P2X is a ligand gated ion channel.
Mast cells from most species express P1Rs: A1, A2A, A2B, and A3
adenosine receptors (Hua et al., 2011). Additionally they express
a large variety of P2R. hCBMC, for example, express P2X1, P2X4,
P2X7, P2Y1, P2Y2 (Bulanova and Bulfone-Paus, 2010), P2Y12,
P2Y13, and P2Y11 (Feng et al., 2004), while mBMMC (derived
from C57BL/6 mice) express the mRNA of P2X1–4, P2X6–7, and
all P2Y receptors with the exception of P2Y2. P815 mastocytoma
cells (derived from DBA/2 mice) express mRNA for all P2X and
P2Y receptors (Bulanova and Bulfone-Paus, 2010). Activation of
P2XR leads to the formation of a non-selective cationic chan-
nel (Burnstock, 2007), that triggers the activation of a number of
intracellular signaling molecules, including MAPK, which is con-
nected to cytokine secretion and release. ATP induces purinergic
receptor P2X7 mediated membrane permeabilization, apoptosis,
and cytokine expression in murine MC (Bulanova et al., 2009).
Stimulation of P2YR generally leads to phospholipase C (PLC)
activation that cleaves PI(4,5)P2 to form IP3 and diacylglycerol,
an activator of protein kinase C (PKC). Only the P2Y11 receptor is
directly coupled to activation of adenylate cyclase (AC) and PLC,
while P2Y12, P2Y13, and P2Y14 receptors negatively affect cAMP
synthesis (Van Kolen and Slegers, 2006). Extracellular nucleotides
activating P2 receptors are involved in the regulation of MC
degranulation. P2Y13 receptor in a rat MC line (RBL-2H3) activa-
tion by ADP leads to intracellular calcium mobilization and release
of β-hexosaminidase. Nucleotides via P2Y2 mediate chemotaxis in
mBMMC and CD34+ progenitors (Bulanova and Bulfone-Paus,
2010).
ATP acts as an autocrine and paracrine factor that enables the
intercellular communication. MC IgE-dependent degranulation
induces the release of ATP that influences the neural cells via P2X
and P2Y receptors (Bulanova and Bulfone-Paus, 2010).
A study recently reported by Yip et al. showed a biphasic effect
of adenosine in hCBMCs, implicating the A1R in potentiation, and
A2BR receptor in the inhibition of anti-IgE-induced degranulation
(Yip et al., 2009; Hua et al., 2011). Interestingly, also leukotriene
E4 acts as ligand for P2Y12 in LAD-2 cells. In addition it can
induce purinergic receptor mediated pulmonary inflammation
in mice (Paruchuri et al., 2009). It has been shown that adeno-
sine binding to P1R on airway smooth muscle, goblet cells, MC,
and neurons contributes to the pathogenesis of asthma (Okayama
et al., 2008; Vieira et al., 2011). Adenosine inhibits and potenti-
ates IgE-dependent histamine release from human lung MCs by
an A2-purinoceptor mediated mechanism (Hughes et al., 1984).
Xanthine derived drugs such as theophylline that have been
widely used for asthma, have been found to be both antag-
onists/agonists of adenosine receptors and phosphodiesterase
inhibitors on MC. Several antagonists are currently available for
research use, such as suramine (Gever et al., 2006). Although the
purinergic receptors are well described in the nervous system, their
discovery on MC is still relatively new and further research is
required in order to understand their specific function and effects
on these cells.
CD203c
CD203c (E-NPP3) belongs to a family of ecto-nucleotide
pyrophosphatase/phosphodiesterases (E-NPPs) that catalyzes the
cleavage of phosphodiester and phosphosulfate bonds of a vari-
ety of molecules, including deoxynucleotides NAD and nucleotide
sugars (Buhring et al., 2004). These type II TM proteins are com-
posed of a short N-terminal cytoplasmic domain, followed by the
TM region, two somatomedin-like domains, the catalytic domain
and a C-terminal endonuclease-like domain. Recently, CD203c has
been defined as a novel activation-linked surface antigen on MC
that is upregulated in response to IgE receptor cross-linking and is
overexpressed on neoplastic MC in patients with systemic masto-
cytosis (Hauswirth et al., 2008). CD203c on basophils serves as a
marker to diagnose various allergic diseases such as asthma (Ono
et al., 2010). The expression and role of ATP-hydrolyzing enzymes
for the biology of MC is still under investigation.
CORTICOTROPIN-RELEASING HORMONE AND
ENDOCANNABINOIDS
Even though Corticotropin-releasing hormone (CRH) and endo-
cannabinoids receptors have been typically described as cen-
tral nervous system (CNS) receptors involved in regulation of
the hypothalamic–pituitary–adrenocortical axis and in drugs
response (Goeders and Guerin, 2000; Steiner and Wotjak, 2008),
these receptors have also been found to be expressed on
hematopoietic cells thus regulating peripheral conditions.
CORTICOTRICOTROPIN RELEASING HORMONE RECEPTORS
Corticotricotropin releasing hormone receptors (CRHRs) are
GPCRs which are activated by urocortin (UCN), CRH, or sub-
stance P and consist of two receptors-CRH-R1 and CRH-R2, each
encoded by a separate gene (Theoharides et al., 1998; Slomin-
ski et al., 2001; Asadi et al., 2012). CRHR signaling involves
cAMP/PKA pathway or alternatively MAPK or intracellular cal-
cium (Ca2+)/PKC pathways, depending on the site of activation
(Grammatopoulos, 2011).
CRH-R1 is sensitive to β-arrestin-dependent signaling desen-
sitization and internalization. Receptor endocytosis is also one of
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the mechanisms employed by CRH-R1 to induce ERK1/2 and p38
MAPK phosphorylation and activation intermediates (Markovic
et al., 2008). CRH-R1 variant is expressed in a tissue-specific man-
ner; it is present in anterior pituitary as well as in peripheral
sites such as reproductive tissues (myometrium, endometrium,
and chorion trophoblast cells) and MC (Nezi et al., 2010).
Corticotropin-releasing hormone is secreted under stress and
activates the hypothalamic–pituitary–adrenal axis. Interestingly a
similar network is found in the skin (Asadi et al., 2012). Addi-
tion of CRH to the LAD-2 (leukemia MC line cells) primed with
substance P induces synthesis and release of IL-8, TNF, and vas-
cular endothelial growth factor (VEGF) 24 h later (Asadi et al.,
2012). MC activation by CRH induces gene expression of neu-
rokinin (NK-1). The ability of CRH to activate MC may explain
its pro-inflammatory actions and the pathophysiology of certain
skin conditions, which are precipitated or exacerbated by stress,
such as atopic dermatitis, eczema, psoriasis, and urticaria (Theo-
harides et al., 1998). CRH has pro-inflammatory actions not only
on its own, but also by augmenting the expression of the respective
receptors on human skin MC (Asadi et al., 2012).
ENDOCANNABINOIDS RECEPTORS
The cannabinoid receptors are a class of cell membrane recep-
tors belonging to the GPCRs superfamily. They contain seven
TM spanning domains and are divided into two subtypes, termed
cannabinoid 1 (CB1) and cannabinoid 2 (CB2). The endocannabi-
noid system has been recognized as a major neuromodulatory sys-
tem, which functions to maintain brain homeostasis (Steiner and
Wotjak, 2008). The CB1 receptor is expressed mainly in the brain
CNS, but also in the lungs, liver, and kidneys. The CB2 receptor
is expressed mainly in the immune system and in hematopoietic
cells (Pacher and Mechoulam, 2011).
CB1 was found to be expressed on human skin MC (Sug-
awara et al., 2012) and be activated by endocannabinoids such
as anandamide (AEA) and 2-arachidonoylglycerol. CB1 and CB2
receptors can induce inhibition of adenylate cyclase activity and
phosphorylation with activation of p42/p44 MAPK, p38 MAPK,
and JNK as signaling pathways to regulate nuclear transcription
factors. The CB1 receptor regulates K+ and Ca2+ ion channels,
probably via Go/i (Howlett, 2005). A common role of CB1 and
CB2 receptors appears to be the modulation of ongoing release of
chemical messengers. The activation of CB2 receptors on MC has
direct anti-inflammatory effects due to a decrease in mediators
released from the cells (Pini et al., 2012).
The best CB2-selective agonists that have been developed so
far include L-759633, L-759656, and JWH-133, all structural
analogs of D9-THC. Other notable examples are the non-classical
cannabinoid, HU-308, and the aminoalkylindole, AM1241 (Per-
twee, 2006). The activation of CB1 receptor on bronchial nerve
ending has a bronchodilatory effect (Pini et al., 2012). However,
inhibiting the enzymatic inactivation of pharmacologically active
endogenous molecules that do not serve as endocannabinoids or
causing an accumulation of endocannabinoid molecules at non-
CB1, non-CB2 targets such as the TRPV1 receptor or the putative
abnormal-cannabidiol receptor, might lead to adverse effects.
Endocannabinoids limit excessive MC maturation and acti-
vation in human skin in situ and regulate SCF expression, by
increasing its production in human hair follicle epithelium via
CB1 stimulation (Sugawara et al., 2012). On the other hand in
the ovalbumin induced lung sensitization model in CB1 and CB2
deficient mice a reduction in IgE production and attenuation of
bronchoalveolar lavage fluid neutrophilia was described (Kaplan
et al., 2010). In some studies, activation of CB1R seems to inhibit
the allergic inflammation, while in others it is still controversial.
Either way, we can conclude that CB1R activation is a potential tar-
get to be used in the treatment of allergy, although further research
is still required.
MC RECEPTORS CROSS-TALK
Cross-talk between receptors might result in co-activation or in
inhibition of cell response. Co-stimulation is often required for the
development of an effective immune response, and has been rec-
ognized to participate in antigen-specific signal from lymphocytes
antigen receptors. In the last few years, parallel to the identification
of the new MC receptors, some cross-talk effects between recep-
tors were described, resulting either in co-activation (synergism
or additive effects) or in inhibition. Most of the works have dealt
with the FcεRI mediated MC activation. For example IL-18R, IL-
33R, TSLP, and TLRs were found to work via the same signaling
pathway which activates MyD88, IRAK, TRAF, and MAPK and
NF-kB (Figure 1). GPCRs on MC can also co-interact to produce
different responses.
MC CO-STIMULATION
Due to co-stimulation and cross-talk significance in modulation
of MC activity, we chose to review some recent examples of this
phenomenon. CCRs are known stimulatory and co-stimulatory
molecules expressed on MC. Fifadara et al. showed for the first time
the formation of cytoneme-like cellular extensions by BMMC, a
totally new feature of these cells, upon co-stimulation of FcεRI
and CCR1 with antigen and CCR1 ligand, macrophage inflamma-
tory protein-1α. This co-stimulation was more effective in some
morphology changes and mediator release than FcεRI stimula-
tion alone (Fifadara et al., 2010). Thus, CCR can contribute to the
inflammatory and allergic responses by formation of cytonemes,
as a way to communicate between MC and other cells. Recently,
the same group has identified 32 genes that were differentially
regulated by a co-stimulation of antigen and the CCR1 ligand
CCL3, compared to stimulation with antigen or CCL3 alone, in
RBL-CCR1 transfected cells. Four genes were mostly up regulated
3 h post co-stimulation (Ccl7, Rgs1, Emp1, RT1-S3), but only the
CCL7 protein was expressed at a higher level 24 h following co-
stimulation. Among chemokines and cytokines tested, only CCL2
protein showed higher expression levels and IL-6 was seen only
after co-stimulation, although in a very low level (Aye et al., 2012).
The authors suggested therefore that CCL2, CCL7, and IL-6 may
be important for MC regulation in the late phase of the allergic
response.
Another novel example of co-stimulation is the one between
FcεRI and adenosine receptor. Nunomura et al. showed that co-
stimulation of a low antigen dose together with adenosine can
induce MC degranulation in a synergistic way, through coopera-
tion of the two receptors mediated signaling. This was suggested
to be relevant to the immediate asthma response upon bronchial
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FIGURE 1 | Mast cells co-activation by IL-18, IL-33,TSLP, andTLR receptors.
challenge with low-dose allergen (Nunomura et al., 2010). It has
also been shown that mBMMC mutant in the FcεRIβ-chain-ITAM
could not be degranulated upon co-stimulation, through PI3K-
signaling pathway (Nunomura et al., 2010). These findings can
provide more detailed insight to which and how specific parts
of the β chain and the PI3K-signaling are important for MC
co-activation.
In mouse MC, thrombin, a serine protease, by binding to
the protease-activated receptor (PAR)-1 TRAP(14) induces the
secretion of IL-6 in a dose dependent fashion, but not of TNFα.
Co-stimulation of low level thrombin with an allergen, can syner-
gistically enhance IL-6 secretion through FcεRI signaling and the
PI(3) and sphingosine-kinase pathways (Gordon et al., 2000).
Drube et al. reported a cross-activation of IL-33R and c-kit
receptor in human and murine MC, after joining of IL-33R upon
ligand binding, to a constitutively bound complex composed of
c-kit and IL-1R accessory protein. In primary MC, the c-kit ligand
SCF, is necessary for IL-33 induced cytokine production (Drube
et al., 2010). Silver et al. showed that IL-33 in HMC-1 cells induced
a synergistic activation effect together with adenosine, C5a, SCF,
and NGF receptors. In primary hMC, IL-33R was also synergized
with FcεRI activation (Silver et al., 2010).
CD48 was found to be a co-stimulatory receptor for inducing
different effects in various hematopoietic cells by binding several
ligands (Elishmereni and Levi-Schaffer, 2011). We have recently
found that hCBMC and eosinophils can be directly activated by
CD48 ligand/s (Elishmereni et al., 2011). In addition we detected
some co-stimulatory effects when CBMC were activated by IgE-
dependent mechanisms (Minai-Fleminger, Y., Levi-Schaffer, F.,
unpublished data).
CD84 is a self binding receptor from the signaling lymphocyte
activating molecules (SLAM) family. However it was shown on
transfected RBL-2H3 cells to inhibit FcεRI degranulation (Oliver-
Vila et al., 2008). Additionally CD84 was found to be expressed on
hMC (Alvarez-Errico et al., 2011), and shown to be tyrosine phos-
phorylated upon co-stimulation with FcεRI. This led to reduction
in granule release and in the release of IL-8 and GM-CSF in LAD-2
cells and human CD34+ derived MC (Alvarez-Errico et al., 2011).
As reported in the past by our group, MC express DNAX acces-
sory molecule 1 (DNAM-1, CD226) and eosinophils express its
ligand Nectin-2 (CD112). It was shown that CD226 engagement
with FcεRI induces an activating synergistic effect on MC and
blocking of the ligand CD112 reduced the hyperactivity caused by
IgE-dependent MC activation (Bachelet et al., 2006). To conclude,
these few examples of co-stimulatory responses on MC can pos-
sibly help in understanding and foreseeing the complex allergic
inflammatory response and be essential for the development of
new anti-allergic therapy.
MC INHIBITORY RECEPTORS AND MC INHIBITION
Inhibitory receptors classically described on NK (Cantoni et al.,
1999; for review, see Pegram et al., 2011) comprise two main
families of the Ig receptor super-family and the c-type (calcium
dependent) lectin superfamily. On MC, FcγRIIB, CD300, CD72,
and sialic acid binding Ig-like lectins (Siglec)8, 7, etc., have been
described (Karra and Levi-Schaffer, 2011). Since the FcγRIIB
receptor has been extensively investigated (see Daeron et al., 2008;
Bruhns et al., 2009) and we discussed some receptors bringing
about MC inhibition, such as CB1, under their respective families,
here we will consider only the most newly described typical IRs.
Inhibitory receptors expressed on MC can modulate their func-
tion by inhibiting typically the signaling from receptors associated
with tyrosine kinases, i.e., FcεRI and c-kit (Figure 2). IRs con-
tain immunoreceptor tyrosine based inhibition motifs (ITIMs)
that down regulate the activation signals transmitted through
immunoreceptor tyrosine based ligand ITAMs. The engagement
of IRs suppresses cell activation by promoting dephosphoryla-
tion reactions. Upon activation of ITIM-containing receptors,
tyrosine residues within the motifs become phosphorylated. This
leads to the recruitment of protein phosphatases, Src homol-
ogy 2 (SH) domain containing protein tyrosine phosphatase-1/2
(SHP-1 and SHP-2) and lipid phosphatases SH2 domain bearing
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FIGURE 2 | Inhibition of MC maturation by CB1 or by a classical IR receptor. (A) CB1 inhibition effect. (B) Inhibition of c-kit mediated signaling by an
inhibitory receptor (IR). Downstream molecules to CB1 or to c-kit cross-linked with the inhibitory receptor (cross-linking is mandatory to inhibitory effect).
inositol phosphatase (SHIP1). SHP-1/2 inhibits the action of tyro-
sine kinase, while SHIP1 terminates the PI3K-mediated pathway
(Karra and Levi-Schaffer,2011). Herewith we are going to illustrate
the CD300a, Siglec 7 and 8, and CD72 IRs.
The CD300 family of myeloid immunoglobulin receptors
includes activating (CD300b, CD300e) and inhibitory (CD300a,
CD300f) members, as well as molecules of uncertain functions
presenting a negative charge within their TM domain (CD300c,
CD300d; Martinez-Barriocanal et al., 2010). None of the activat-
ing receptors identified contains a charged glutamic acid residue
in the TM that is present in CD300c, suggesting that CD300c
might deliver activating signals via signaling proteins other than
those previously observed or that CD300c is not an activating
receptor (Lankry et al., 2010). The function of CD300d is related
to the regulation of the expression of other CD300 molecules
and the composition of CD300 complexes on the cell surface
(Comas-Casellas et al., 2012).
The CD300 IR are type I TM glycoproteins with a single IgV-
like extracellular domain and a membrane proximal region, a TM
region, and a cytoplasmic region with ITIM motif (Lankry et al.,
2010). The cytoplasmic domains of CD300a and CD300f con-
tain internalization motifs and the cell surface expression of these
molecules might be regulated, in part, by internalization (Clark
et al., 2009). The expression of CD300a and CD300f was shown
in MC (Clark et al., 2009), where CD300a presents on MC from
nasal polyps, lungs, and on hCBMC (Bachelet et al., 2005) and its
mouse ortholog LMIR-1, is expressed on mBMMC (Kumagai et al.,
2003). CD300a is also expressed on NK, T cell subsets, neutrophils,
eosinophils, monocytes DC, and more recently it has been char-
acterized on basophils (Cantoni et al., 1999; Bachelet et al., 2005;
Munitz et al., 2006a; Alvarez et al., 2008; Sabato et al., 2012).
It has been recently reported that CD300a interacts with polar
lipids, including the major phospholipids of cell membranes, and
is able to transduce intracellular signals after lipid binding. One
of CD300a ligands is phosphatidylserine which directly binds
CD300a and phosphorylates ITIM in the cytoplasmic portion of
CD300a on BMMC (Nakahashi-Oda et al., 2012). Interestingly,
Simhadri showed that CD300a phosphatidylethanolamine and
phosphatidylserine bind to CD300a, and modulate the phagocy-
tosis of dead cells. CD300a down regulates the uptake of apoptotic
cells by macrophages and its ectopic expression in CD300a-
negative cell lines also decreased the engulfment of dead cells
(Simhadri et al., 2012). Using a co-transfection assay on THP-1
cells, Kim et al. (2012) showed that while CD300a blocked only
MyD88 induced events, CD300f blocked both MyD88 and TRIF.
CD300a reduced survival of MC and eosinophils by decreas-
ing the effect of c-kit on MC, and the IL-5, GM-CSF effect on
eosinophils (Bachelet et al., 2005, 2008). Moreover a bi-specific
Ab to CD300a and IgE inhibited acute airway inflammation in an
experimental asthma mouse model and passive cutaneous anaphy-
laxis (Bachelet et al., 2008). Also a bi-specific Ab against CD300a
and CCR3 inhibited chronic airway inflammation in murine
asthma, possibly by its binding on both MC and eosinophils and
their consequent inhibition (Munitz et al., 2006b). Disease-wise
there is evidence for alterations in the expression and function
of the CD300 family in patients with psoriasis (Clark et al.,
2009).
Siglec-8 appears on hMCs at the same time as other MC mark-
ers such as FcεRI (Karra et al., 2009). When cross-linked by
mAbs on hpbMC, Siglec-8 does not lead to apoptosis as it does
on eosinophils, but rather to strong inhibition of histamine and
prostaglandin D2 secretion and of [Ca2+] influx (Yokoi et al.,
2008; Bochner, 2009; Karra et al., 2009). Siglec-8 is known to
specifically recognize the sialoside sequence 6′-sulfo-sLex (Tateno
et al., 2005). Siglec-8 has been shown to be associated with
asthma (Gao et al., 2010). We have found Siglec 7, another lectin-
binding IR, that was previously described on eosinophils (Munitz
et al., 2006a) to be expressed and functional on hMC (Mizrahi,
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S., Karra, L., Ben Zimra, M., and Levi-Schaffer, F., unpublished
data).
CD72 (Lyb-2) is an ITIM-containing 45 kDa type II TM pro-
tein of the C-type lectin family (Wu and Bondada, 2009) whose
natural ligands have been identified as CD100 or Semaphorin 4D
(Sema4D). CD72, which is considered to be an important co-
receptor regulating B-cell activation (Wu and Bondada, 2009), is
also expressed on mouse NK cells (Alcon et al., 2009) and on
hPBMC and human cell lines (Kataoka et al., 2010). Ligation
of CD72 reduced SCF-mediated proliferation, chemotaxis, and
MCP-1 (or CCL2) production in hMCs and the suppression of
growth of HMC-1.2 harboring the gain-of-function mutation in
KIT gene (Kataoka et al., 2010).
In conclusion IR, that have been shown to mostly modulate on
MC the activation of FcεRI and c-kit, may have by themselves or
by cooperation with other receptors, inhibitory functions on other
receptors not necessarily linked to tyrosine kinases mechanism,
although this still has to be thoroughly investigated.
CONCLUSION
Mast cells express a variety of receptors that enable them, both in
activating or inhibiting ways, to modulate immune response and
can be used as treatment targets in disease conditions. While with
some of the described receptors such as H4 and purinergic recep-
tors, we are close to developing a drug, with others, such as TSLP,
more basic studies on their functions are needed. Overall, evi-
dences show that MC receptors have a strong therapeutic potential
but still a better understanding of their pathophysiological roles,
expression and their role in the immune system is required in order
to develop effective and side effect free therapeutic interventions
in the near future.
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